Reply from Authors re: Michael Baum. Screening for prostate cancer: Can we learn from the mistakes of the breast screening experience? Eur Urol 2013;64:540-1: Screening for prostate cancer: We have learned and are still learning

European Urology

Volumn 64, Issue 4, 2013, Pages 541-543

  Roobol, Monique J ^a   Kranse, Ries ^b   Bangma, Chris H ^a   Otto, Suzie J ^a   Van Der Kwast, Theo H ^a   Bokhorst, Leonard P ^a   De Koning, Harry J ^a   Schröder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Integraal Kankercentrum Rotterdam   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; FOLLOW UP; HUMAN; LETTER; LIFESPAN; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; TREATMENT REFUSAL;

HUMANS; KALLIKREINS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84883776335     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.06.033     Document Type: Editorial

References (16)

1. M. Baum Screening for prostate cancer: can we learn from the mistakes of the breast screening experience? Eur Urol 64 2013 540 541
2. H.J. De Koning, T. Hakulinen, and S.M. Moss Monitoring the ERSPC trial BJU Int 92 Suppl 2 2003 112 114
3. F.H. Schröder, J. Hugosson, and M.J. Roobol Screening and prostate cancer mortality in a randomised European study N Engl J Med 360 2009 1320 1328
4. F.H. Schröder, J. Hugosson, and M.J. Roobol Prostate cancer mortality at 11 years of follow-up N Engl J Med 366 2012 981 990
5. M.J. Roobol, R. Kranse, and C.H. Bangma Screening for prostate cancer: results of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer Eur Urol 64 2013 530 539
6. E.A. Heijnsdijk, E.M. Wever, and A. Auvinen Quality-of-life effects of prostate-specific antigen screening N Engl J Med 367 2012 595 605
7. G. Draisma, R. Boer, and S.J. Otto Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer JNCI 95 2003 868 878
8. S. Ciatto, M. Zappa, and A. Villers Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening BJUI 92 Suppl 2 2003 97 100
9. S.J. Otto, I.W. van der Cruijsen, and M.K. Liem Effective PSA contamination in the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer Int J Cancer 105 2003 394 399
10. M.J. Roobol, M. Kerkhof, and F.H. Schröder Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC) Eur Urol 56 2009 584 591
11. F.H. Schröder, J. Hugosson, and S. Carlsson Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized study of Screening for Prostate Cancer (ERSPC) Eur Urol 62 2012 745 752
12. J. Ferlay, H.R. Shin, and F. Bray Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2893 2917
13. F. Bray, A. Jemal, and N. Grey Global cancer transitions according to the Human Development Index (2008-2030): a population-based study Lancet Oncol 13 2012 790 801
14. The World Health Organisation (2008). 2008-2013 action plan for the global strategy for the prevention and control of noncommunicable diseases: prevent and control cardiovascular diseases, cancers, chronic respiratory diseases and diabetes. World Health Organization Web site. http://www.who.int/ nmh/publications/9789241597418/en/index.html. Accessed June 3, 2013.
15. General Assembly of the United Nations. President of the 65th Session. High-Level Meeting on Non-communicable Diseases. General Assembly of the United Nations Web site. http://www.un.org/en/ga/president/65/issues/ncdiseases.shtml. Accessed June 3, 2013.
16. M.G. Marmot, D.G. Altman, and D.A. Cameron The benefits and harms of breast cancer screening: an independent review Lancet 380 2012 1778 1786